Wells Fargo & Company Cuts WAVE Life Sciences (NASDAQ:WVE) Price Target to $13.00

WAVE Life Sciences (NASDAQ:WVE) had its price objective dropped by equities researchers at Wells Fargo & Company from $27.00 to $13.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price indicates a potential upside of 109.68% from the company’s previous close.

A number of other brokerages also recently commented on WVE. Citigroup upped their target price on WAVE Life Sciences from $16.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Morgan Stanley set a $28.00 price target on shares of WAVE Life Sciences in a report on Monday, December 8th. Oppenheimer boosted their price objective on shares of WAVE Life Sciences from $24.00 to $32.00 and gave the company an “outperform” rating in a research report on Tuesday, December 16th. Cantor Fitzgerald upped their price objective on shares of WAVE Life Sciences from $34.00 to $41.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Finally, B. Riley Financial raised their target price on shares of WAVE Life Sciences from $19.00 to $37.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, WAVE Life Sciences presently has an average rating of “Moderate Buy” and an average price target of $32.44.

WAVE Life Sciences Price Performance

NASDAQ WVE opened at $6.20 on Friday. WAVE Life Sciences has a 1 year low of $5.02 and a 1 year high of $21.73. The stock has a market capitalization of $1.17 billion, a PE ratio of -5.08 and a beta of -1.77. The business’s 50-day moving average is $13.08 and its 200 day moving average is $11.20.

WAVE Life Sciences (NASDAQ:WVE) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.02). WAVE Life Sciences had a negative net margin of 478.35% and a negative return on equity of 85.69%. The business had revenue of $17.25 million for the quarter, compared to the consensus estimate of $15.68 million. As a group, equities research analysts anticipate that WAVE Life Sciences will post -1.14 earnings per share for the current year.

Insider Transactions at WAVE Life Sciences

In related news, CEO Paul Bolno sold 10,480 shares of WAVE Life Sciences stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $13.45, for a total transaction of $140,956.00. Following the sale, the chief executive officer directly owned 275,520 shares in the company, valued at $3,705,744. The trade was a 3.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Kyle Moran sold 3,588 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $13.45, for a total value of $48,258.60. Following the completion of the sale, the chief financial officer directly owned 134,385 shares in the company, valued at approximately $1,807,478.25. The trade was a 2.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 61,748 shares of company stock worth $907,809. 23.98% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. GSK plc bought a new stake in WAVE Life Sciences during the fourth quarter worth about $310,177,000. Adage Capital Partners GP L.L.C. increased its stake in shares of WAVE Life Sciences by 20.0% during the second quarter. Adage Capital Partners GP L.L.C. now owns 15,016,500 shares of the company’s stock valued at $97,607,000 after purchasing an additional 2,500,000 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of WAVE Life Sciences by 83.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,407,372 shares of the company’s stock valued at $125,927,000 after purchasing an additional 3,362,880 shares in the last quarter. Darwin Global Management Ltd. purchased a new position in shares of WAVE Life Sciences during the fourth quarter valued at approximately $125,168,000. Finally, Federated Hermes Inc. boosted its position in shares of WAVE Life Sciences by 26.5% in the 4th quarter. Federated Hermes Inc. now owns 4,744,520 shares of the company’s stock worth $80,657,000 after purchasing an additional 993,827 shares in the last quarter. 89.73% of the stock is currently owned by institutional investors.

Key Headlines Impacting WAVE Life Sciences

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: Mizuho raised its price target and maintained an outperform view on WVE, forecasting significant upside vs. the current price — a bullish analyst signal ahead of the trial update. Mizuho price target raise
• Positive Sentiment: Truist upgraded WAVE to “strong‑buy” (reported via Zacks), indicating some institutional conviction prior to the trial data release. Truist upgrade / Zacks
• Neutral Sentiment: Company press release: a single 240 mg dose of WVE‑007 produced placebo‑adjusted improvements at six months — visceral fat down ~14.3%, total fat down ~5%, lean mass +2%, waist −3.3%, and weight −0.9% — and reported continued tolerability. Company INLIGHT press release
• Negative Sentiment: Investors punished the stock after headlines emphasized the underwhelming weight‑loss and mixed higher‑dose results; multiple outlets reported a >50% intraday plunge as traders reassessed commercial prospects. Reuters: shares plunge
• Negative Sentiment: Coverage framed the readout as “underwhelming” (minimal weight change despite visceral‑fat signals), leading to downgrades and skeptical analyst commentary questioning near‑term commercial potential. Seeking Alpha: downgrade
• Negative Sentiment: A plaintiff‑side law firm (Johnson Fistel) announced an investigation into potential investor claims related to WAVE’s disclosures, which can increase legal risk and weigh on sentiment. Johnson Fistel investigation

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.